Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • msxakk
    Junior Member
    • Jul 2015
    • 1

    #1

    Meaning of differential promoter use (cuffdiff)

    Hi All,

    Can somebody explain to me how is differential promoter use inferred from RNAseq data ? Here I'm talking about the way it is implemented by cuffdiff (I followed TUXEDO pipeline). In the documentation it says:

    " This tab delimited file lists, for each gene, the amount of overloading detected among its primary transcripts, i.e. how much differential promoter use exists between samples. Only genes producing two or more distinct primary transcripts (i.e. multi-promoter genes) are listed here. "

    What is considered a primary transcript? Is it equivalent to pre-mRNA ? If my library is poly(A) enriched it shouldn't be rich for pre-mRNAs yet I still get a result (TEST STATUS OK) for some of the genes. I understand that poly(A) enrichment is not ideal and hence there could have been some reads derived from pre-mRNAs but in that case I would have been limited by stochastic forces ? Hence making comparisons between conditions would be challenging. And finally why would differential levels of pre-mRNA indicate differential promoter usage and why only genes producing two or more distinct primary transcripts would be included in analysis while the rest would not?

    Thanks
  • Bukowski
    Senior Member
    • Jan 2010
    • 388

    #2
    Crossposted to BioStars: https://www.biostars.org/p/151531/

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
      by SEQadmin2



      CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

      Despite this, “CRISPR helped turn genome editing from a specialized technique into
      ...
      07-31-2026, 11:01 AM
    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 08-06-2026, 07:41 AM
    0 responses
    21 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 08-03-2026, 10:13 AM
    0 responses
    33 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-31-2026, 02:55 AM
    0 responses
    43 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-24-2026, 12:17 PM
    0 responses
    26 views
    0 reactions
    Last Post SEQadmin2  
    Working...